Rationale: The aim of this study is to investigate if following the implementation of the Regulation EU/1235/2010 and the Directive 2010/84/EU there was an increase of individual case safety reports (ICSRs) deriving from a medication error, abuse, misuse, overdose, or occupational exposure. Other objectives are the identification of drugs mostly involved in such cases, to establish if the codification of aforementioned conditions is performed correctly and, whenever codification errors exist, to identify predictors of codification errors. Finally, we estimated the magnitude of these errors on signal detection activities. Methods: ICSRs sent through Campania Region (Italy) spontaneous reporting system from July 2nd 2012 to December 31th 2017...
Background: Drug-drug interactions (DDIs) are an important cause of adverse drug reactions (ADRs). M...
Objective: To describe the evolution of adverse drug reactions (ADRs) spontaneously reporting in the...
The role of patients as key contributors in pharmacovigilance was acknowledged in the new EU pharmac...
Rationale: The aim of this study is to investigate if following the implementation of the Regulation...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
Background: The reporting of adverse drug reactions (ADRs) is the mainstay of post-marketing surveil...
<p><b>Background</b>: The number of suspected adverse drug reactions (ADRs) yearly submitted to the ...
Objectives: To characterize adverse reactions associated with medication errors (ME) reported in US ...
Background: Spontaneous reporting of suspected adverse drug reactions (ADR) is considered the eorner...
Introduction: Spontaneous reporting of adverse drug reactions (ADRs) is the basis of pharmacovigilan...
Background: Drug-drug interactions (DDIs) are an important cause of adverse drug reactions (ADRs). M...
Objective: To describe the evolution of adverse drug reactions (ADRs) spontaneously reporting in the...
The role of patients as key contributors in pharmacovigilance was acknowledged in the new EU pharmac...
Rationale: The aim of this study is to investigate if following the implementation of the Regulation...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
<p>Rationale: The aim of this study is to investigate if following the implementation of the Regulat...
Background: The reporting of adverse drug reactions (ADRs) is the mainstay of post-marketing surveil...
<p><b>Background</b>: The number of suspected adverse drug reactions (ADRs) yearly submitted to the ...
Objectives: To characterize adverse reactions associated with medication errors (ME) reported in US ...
Background: Spontaneous reporting of suspected adverse drug reactions (ADR) is considered the eorner...
Introduction: Spontaneous reporting of adverse drug reactions (ADRs) is the basis of pharmacovigilan...
Background: Drug-drug interactions (DDIs) are an important cause of adverse drug reactions (ADRs). M...
Objective: To describe the evolution of adverse drug reactions (ADRs) spontaneously reporting in the...
The role of patients as key contributors in pharmacovigilance was acknowledged in the new EU pharmac...